LOX and systemic sclerosis: By inhibiting all isoforms of lysyl oxidases, the novel pan-lysyl oxidase inhibitor PXS-5505 successfully ameliorates aggressive fibrosis progression and may therefore be suitable for treating severe fibrotic diseases such as SSc.